It has been 10 years since Sitagliptin was approved by the FDA. When it was first approved there was a lot of pushback from prescribers to trying a new class, as the last class, the TZDs, had suffered through the problems with Rezulin and the cardiovascular problems associated with Actos and Avandia.
Although sales started slowly, the drug known as Januvia became a billion dollar blockbuster for Merck, and many other companies have tried to capture some of Januvia’s success with their own versions of a DPP-4I.
There are currently eleven approved DPP-4I available around the world, and the list is continuing to grow as another three are in development. In addition, Merck has a once a week version, omarigliptin, available in Japan.
This month we have an overview of the available ones, as well as ways to adjust dosing for special populations.